Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
Which of the following may reduce binging and purging in adolescents with eating disorders, including anorexia nervosa?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 185 - 202Publisher: Cambridge University PressPrint publication year: 2023
References
Birmingham, C. L. Assessment and treatment of acute medical complications during the refeeding process. In Jaffa, T. (ed.), Eating Disorders in Children and Adolescents. Cambridge, UK: Cambridge University Press, 2006. https://doi.org/10.1017/CBO9780511543890.016Google Scholar
Frederiksen, T. C., Christiansen, M. K., Østergaard, P. C., et al. QTc interval and risk of cardiac events in adults with anorexia nervosa. A long-term follow-up study. Circ Arrhyth Electrophysiol 2018; 11(8): e005995. https://doi.org/10.1161/CIRCEP.117.005995Google Scholar
Cotter, R., Lyden, J., Mehler, P. S., et al. A case series of profound bradycardia in patients with severe anorexia nervosa: thou shall not pace? HeartRhythm Case Rep 2019; 5(10): 511–15. https://doi.org/10.1016/j.hrcr.2019.07.011Google Scholar
Han, R., Bian, Q., Chen, H. Effectiveness of olanzapine in the treatment of anorexia nervosa: a systematic review and meta-analysis. Brain Behav 2022; 12(2): e2498. https://doi.org/10.1002/brb3.2498Google Scholar
Kask, J., Ekselius, L., Brandt, L., et al. Mortality in women with anorexia nervosa: the role of comorbid psychiatric disorders. Psychosom Med 2016; 78(8): 910–19. https://doi.org/10.1097/PSY.0000000000000342Google Scholar
Kessler, U., Rekkedal, G., Rø, Ø., et al. Association between gastrointestinal complaints and psychopathology in patients with anorexia nervosa. Int J Eating Disord 2020; 53(5): 802–06. https://doi.org/10.1002/eat.23243Google Scholar
Mehanna, H. M., Moledina, J., Travis, J. Refeeding syndrome: what it is, and how to prevent and treat it. BMJ 2008; 336(7659): 1495. https://doi.org/10.1136/bmj.a301Google Scholar
Mehler, P. S., Blalock, D. V., Walden, K., et al. Medical findings in 1,026 consecutive adult inpatient–residential eating disordered patients. Int J Eating Disord 2018; 51(4): 305–13. https://doi.org/10.1002/eat.22830Google Scholar
Ornstein, R. M., Golden, N. H., Jacobson, M. S., Shenker, I. R. Hypophosphatemia during nutritional rehabilitation in anorexia nervosa: implications for refeeding and monitoring. J Adolesc Health 2003; 32(1): 83–88. https://doi.org/10.1016/S1054-139X(02)00456-1Google Scholar
Sabel, A. L., Gaudiani, J. L., Statland, B., Mehler, P. S. Hematological abnormalities in severe anorexia nervosa. Ann Hematol 2013; 92(5): 605–13. https://doi.org/10.1007/s00277-013-1672-xGoogle Scholar
Sachs, K. V., Harnke, B., Mehler, P. S., Krantz, M. J. Cardiovascular complications of anorexia nervosa: a systematic review. Int J Eating Disord 2016; 49(3): 238–48. https://doi.org/10.1002/eat.22481Google Scholar
Schalla, M. A., Stengel, A. Gastrointestinal alterations in anorexia nervosa: a systematic review. Eur Eating Disord Rev 2019; 27(5): 447–61. https://doi.org/10.1002/erv.2679Google Scholar
Spettigue, W., Norris, M. L., Maras, D., et al. Evaluation of the effectiveness and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescents: an open-label trial. J Can Acad Child Adolesc Psychiatry 2018; 27(3): 197–208. PMID: 30038658Google Scholar
Stancil, S. L., Abdel-Rahman, S., Wagner, J. Developmental considerations for the use of naltrexone in children and adolescents. J Pediatr Pharmacol Ther 2021; 26(7): 675–95. https://doi.org/10.5863/1551-6776-26.7.675Google Scholar
Stancil, S. L., Adelman, W., Dietz, A., Abdel-Rahman, S. Naltrexone reduces binge eating and purging in adolescents in an eating disorder program. J Child Adolesc Psychopharmacol 2019; 29(9): 721–24. https://doi.org/10.1089/cap.2019.0056CrossRefGoogle Scholar
Strawn, J. R., Mills, J. A., Poweleit, E. A., Ramsey, L. B., Croarkin, P. E. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy 2023; 43(7): 675–690.CrossRefGoogle ScholarPubMed